Primary Site >> Colorectal Cancer

Gene >> ADAM17

  • 2004
  • 2005
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Expression patterns of cell cycle and apoptosis-related genes in a multidrug-resistant human colon carcinoma cell line.
PMID: 15180185
Ref: IL-6 signaling promotes tumor growth in colorectal cancer.
PMID: 15655344
Ref: Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells.
PMID: 16041691
Ref: Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells.
PMID: 16213893
Ref: Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line.
PMID: 16597643
Ref: Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling.
PMID: 17220428
Ref: TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer.
PMID: 18281553
Ref: Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
PMID: 18922903
Ref: TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects.
PMID: 19260480
Ref: Nuclear signalling by tumour-associated antigen EpCAM.
PMID: 19136966
Ref: Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
PMID: 19276250
Ref: Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma.
PMID: 19380613
Ref: Drug-eluting bead therapy in primary and metastatic disease of the liver.
PMID: 20495705
Ref: MicroRNA-145 targets YES and STAT1 in colon cancer cells.
PMID: 20098684
Ref: Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation.
PMID: 20334513
Ref: Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
PMID: 20570921
Ref: ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?
PMID: 20570925
Ref: The soluble Interleukin 6 receptor: generation and role in inflammation and cancer.
PMID: 21145125
Ref: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
PMID: 21148749
Ref: Expression of the antiapoptotic protein survivin in colon cancer.
PMID: 21855041
Ref: [alpha-fetoprotein producing rectal cancer].
PMID: 22504700
Ref: The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and gamma-secretase, enhances cell proliferation and migration in colon cancer cells.
PMID: 22665490
Ref: MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.
PMID: 22677042
Ref: First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI).
PMID: 22842404
Ref: ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis.
PMID: 23251384
Ref: Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.
PMID: 23375636
Ref: Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-alpha: impact on gastrointestinal cancers driven by secondary bile acids.
PMID: 24520077
Ref: ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
PMID: 24931611
Ref: The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer.
PMID: 25202035
Ref: Claudin-7 promotes the epithelial-mesenchymal transition in human colorectal cancer.
PMID: 25514462
Ref: Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study.
PMID: 25799948
Ref: A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.
PMID: 26744411
Ref: Expression of Migration-Related Genes in Human Colorectal Cancer and Activity of a Disintegrin and Metalloproteinase 17.
PMID: 27110571
Ref: A novel approach to inoperable or recurrent rectal cancer by chemoembolization: A new arrow in our quiver?
PMID: 27303924
Ref: [A Case of Rectal Neuroendocrine Carcinoma with Metachronous Liver Metastasis Treated with Multimodality Therapy].
PMID: 27539046
Ref: Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway.
PMID: 27874952
Ref: ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer.
PMID: 27489286
Ref: TLR4-mediated galectin-1 production triggers epithelial-mesenchymal transition in colon cancer cells through ADAM10- and ADAM17-associated lactate production.
PMID: 27837433
Ref: 2-Deoxy-D-glucose suppresses the migration and reverses the drug resistance of colon cancer cells through ADAM expression regulation.
PMID: 28059830
Ref: ADAM-17/FHL2 colocalisation suggests interaction and role of these proteins in colorectal cancer.
PMID: 28349819
Ref: Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.
PMID: 29029414
Ref: Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
PMID: 29032738
Ref: Serum levels of ADAM10, ADAM12, ADAM17 AND ADAM28 in colorectal cancer patients.
PMID: 29254295
Ref: Loss of PACS-2 delays regeneration in DSS-induced colitis but does not affect the Apc(Min) model of colorectal cancer.
PMID: 29312533
Ref: Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17.
PMID: 28819788
Ref: ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.
PMID: 29472497
Ref: Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
PMID: 29964008
Ref: A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
PMID: 30069943